Pharmacological treatment of generalized anxiety disorder.

[1]  Dan J Stein,et al.  How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database , 2009, Human psychopharmacology.

[2]  S. Kasper,et al.  Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial , 2009 .

[3]  A. Gamma,et al.  The generalized anxiety spectrum: prevalence, onset, course and outcome , 2009, European Archives of Psychiatry and Clinical Neuroscience.

[4]  A. Gendron,et al.  Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. , 2008, Journal of anxiety disorders.

[5]  S. Montgomery,et al.  Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder , 2008, British Journal of Psychiatry.

[6]  M. Pollack,et al.  Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. , 2008, Journal of psychiatric research.

[7]  Dan J Stein,et al.  Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.

[8]  J. Erickson,et al.  Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial , 2008, European Neuropsychopharmacology.

[9]  H. Eriksson,et al.  P.4.e.005 Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD , 2008, European Neuropsychopharmacology.

[10]  M. Briley,et al.  Resolution of sexual dysfunction during acute treatment of major depression with milnacipran , 2008, Human psychopharmacology.

[11]  D. Stein,et al.  Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies , 2008, European Neuropsychopharmacology.

[12]  Moira Rynn,et al.  Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible‐dose, progressive‐titration, placebo‐controlled trial , 2008, Depression and anxiety.

[13]  J. Davidson,et al.  Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings , 2008, Psychopharmacology.

[14]  Alyson K. Zalta,et al.  Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy , 2008, Depression and anxiety.

[15]  H. Wittchen,et al.  Long-term efficacy of pregabalin in generalized anxiety disorder , 2008, International clinical psychopharmacology.

[16]  J. Davidson,et al.  An effect-size analysis of pharmacologic treatments for generalized anxiety disorder , 2007, Journal of psychopharmacology.

[17]  D. Stein,et al.  P.4.a.016 Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study , 2007, European Neuropsychopharmacology.

[18]  E. Weiller,et al.  Escitalopram Therapy for Major Depression and Anxiety Disorders , 2007, The Annals of pharmacotherapy.

[19]  J. L. R. Martin,et al.  Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials , 2007, Journal of psychopharmacology.

[20]  P. Bech.  Dose-response Relationship of Pregabalin in Patients with Generalized Anxiety Disorder. A Pooled Analysis of Four Placebo-controlled Trials , 2007, Pharmacopsychiatry.

[21]  G. Kinrys,et al.  Adjunctive zonisamide for treatment refractory anxiety , 2007, International journal of clinical practice.

[22]  James Russell,et al.  Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial , 2007, International clinical psychopharmacology.

[23]  D. Baldwin,et al.  Role of pregabalin in the treatment of generalized anxiety disorder , 2007, Neuropsychiatric disease and treatment.

[24]  Z. Segal,et al.  A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. , 2007, The Journal of clinical psychiatry.

[25]  M. Riddle,et al.  Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. , 2007, The American journal of psychiatry.

[26]  S. Montgomery,et al.  Discontinuation symptoms in depression and anxiety disorders. , 2007, The international journal of neuropsychopharmacology.

[27]  E. Rüther,et al.  Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[28]  D. Baldwin,et al.  Generalised anxiety disorder , 2006, The Lancet.

[29]  Dan J Stein,et al.  Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. , 2006, The Journal of clinical psychiatry.

[30]  C. Allgulander,et al.  Prevention of relapse in generalized anxiety disorder by escitalopram treatment. , 2006, The international journal of neuropsychopharmacology.

[31]  D. Stein,et al.  What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? , 2006, The Journal of clinical psychiatry.

[32]  D. Baldwin,et al.  Escitalopram and paroxetine in the treatment of generalised anxiety disorder , 2006, British Journal of Psychiatry.

[33]  M. Thase,et al.  Azapirones for generalized anxiety disorder. , 2006, The Cochrane database of systematic reviews.

[34]  R. Knapp,et al.  Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. , 2006, The Journal of clinical psychiatry.

[35]  S. Kasper,et al.  Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. , 2006, The Journal of clinical psychiatry.

[36]  Alyson K. Zalta,et al.  Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study , 2006, Biological Psychiatry.

[37]  Benjamin F. Rodriguez,et al.  Characteristics and Predictors of Full and Partial Recovery From Generalized Anxiety Disorder in Primary Care Patients , 2006, The Journal of nervous and mental disease.

[38]  K. Rickels,et al.  Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. , 2006, The Journal of clinical psychiatry.

[39]  D. Baldwin,et al.  Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine , 2006, Journal of psychopharmacology.

[40]  J. Cairney,et al.  Community Survey of Bipolar Disorder in Canada: Lifetime Prevalence and Illness Characteristics , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[41]  K. Rickels,et al.  Early response and 8‐week treatment outcome in GAD , 2006, Depression and anxiety.

[42]  Alyson K. Zalta,et al.  Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder , 2006, Depression and anxiety.

[43]  J. A. Boer,et al.  Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology , 2005, Journal of psychopharmacology.

[44]  R. Knapp,et al.  Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. , 2005, The Journal of clinical psychiatry.

[45]  M. Pollack,et al.  Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. , 2005, Archives of general psychiatry.

[46]  W. Goodman,et al.  Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. , 2005, Journal of affective disorders.

[47]  H. Wittchen,et al.  Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies , 2005, European Neuropsychopharmacology.

[48]  M. Keller,et al.  Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. , 2005, The American journal of psychiatry.

[49]  D. Baldwin,et al.  Evidence-based pharmacotherapy of Generalized Anxiety Disorder. , 2005, The international journal of neuropsychopharmacology.

[50]  D. Stein,et al.  Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. , 2005, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[51]  R. Fieve,et al.  Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder: Double-blind, Placebo-Controlled Comparison of BID versus TID Dosing , 2005, Journal of clinical psychopharmacology.

[52]  M. Hautzinger,et al.  A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder , 2005, Journal of clinical psychopharmacology.

[53]  M. Matousek,et al.  Sleep disturbances in patients treated for panic disorder. , 2005, Sleep medicine.

[54]  D. Nutt.  Overview of Diagnosis and Drug Treatments of Anxiety Disorders , 2005, CNS Spectrums.

[55]  T. Johnson,et al.  The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder , 2004, Psychological Medicine.

[56]  D. Baldwin.  Sexual dysfunction associated with antidepressant drugs , 2004, Expert opinion on drug safety.

[57]  C. Frith,et al.  Schizophrenia and theory of mind , 2004, Psychological Medicine.

[58]  C. Clary,et al.  Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. , 2004, The American journal of psychiatry.

[59]  J. Davidson,et al.  Escitalopram in the treatment of generalized anxiety disorder: Double‐blind, placebo controlled, flexible‐dose study , 2004, Depression and anxiety.

[60]  A. Reynolds,et al.  A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. , 2003 .

[61]  M. Pollack,et al.  Predictors of Outcome Following Venlafaxine Extended-Release Treatment of DSM-IV Generalized Anxiety Disorder: A Pooled Analysis of Short- and Long-Term Studies , 2003, Journal of clinical psychopharmacology.

[62]  R. Shrivastava,et al.  A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients With Generalized Anxiety Disorder , 2003, Journal of clinical psychopharmacology.

[63]  D. Sheehan,et al.  Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.

[64]  U. Lepola,et al.  Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. , 2003, The Journal of clinical psychiatry.

[65]  J. Davidson,et al.  Pregabalin in generalized anxiety disorder: a placebo-controlled trial. , 2003, The American journal of psychiatry.

[66]  D. Kupfer,et al.  Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review , 2003, The Lancet.

[67]  G. Perugi,et al.  Open-Label Evaluation of Venlafaxine Sustained Release in Outpatients with Generalized Anxiety Disorder with Comorbid Major Depression or Dysthymia: Effectiveness, Tolerability and Predictors of Response , 2002, Neuropsychobiology.

[68]  M. Höfler,et al.  Generalized anxiety and depression in primary care: prevalence, recognition, and management. , 2002, The Journal of clinical psychiatry.

[69]  D. Sheehan,et al.  Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. , 2002, Journal of psychiatric research.

[70]  K Rickels,et al.  Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. , 2001, The American journal of psychiatry.

[71]  C. Allgulander,et al.  Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder , 2001, British Journal of Psychiatry.

[72]  M. Pollack,et al.  Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. , 2001, The Journal of clinical psychiatry.

[73]  J. Ferguson.  SSRI Antidepressant Medications: Adverse Effects and Tolerability. , 2001, Primary care companion to the Journal of clinical psychiatry.

[74]  R. Kessler,et al.  Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey , 2000, International clinical psychopharmacology.

[75]  A. Gelenberg,et al.  Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. , 2000, JAMA.

[76]  D. Sheehan,et al.  Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. , 2000, The American journal of psychiatry.

[77]  R. Kessler,et al.  Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. , 1999, The American journal of psychiatry.

[78]  J. Ballenger.  Clinical guidelines for establishing remission in patients with depression and anxiety. , 1999, The Journal of clinical psychiatry.

[79]  J. Davidson,et al.  Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. , 1999, The Journal of clinical psychiatry.

[80]  R. Kessler,et al.  Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS) , 1998, Acta psychiatrica Scandinavica. Supplementum.

[81]  A. Beekman,et al.  Anxiety disorders in later life: a report from the longitudinal aging study Amsterdam , 1998, International journal of geriatric psychiatry.

[82]  W. Maier,et al.  Prevalence and recognition of anxiety syndromes in five European primary care settings , 1998, British Journal of Psychiatry.

[83]  T. Baghai,et al.  Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients , 1998, Psychopharmacology.

[84]  M. Pollack,et al.  Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis , 1997 .

[85]  K. Rickels,et al.  Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. , 1988, Archives of general psychiatry.

[86]  J. Mendels,et al.  Effective short-term treatment of generalized anxiety disorder with trifluoperazine. , 1986, The Journal of clinical psychiatry.

[87]  K. Rickels,et al.  Early treatment response in anxious outpatients treated with diazepam , 1985, Acta psychiatrica Scandinavica.

[88]  P. Tyrer,et al.  GRADUAL WITHDRAWAL OF DIAZEPAM AFTER LONG-TERM THERAPY , 1983, The Lancet.

[89]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[90]  Stevenson Gh,et al.  Report on the formation of the Canadian Psychiatric Association. , 1951 .